Trials / Terminated
TerminatedNCT01184508
A Study in Migraine Prevention
A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Administered orally, once daily, for 12 weeks |
| DRUG | LY2300559 | 300 milligrams (mg) administered orally, once daily, for 12 weeks |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-08-19
- Last updated
- 2018-09-12
- Results posted
- 2018-09-12
Locations
12 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01184508. Inclusion in this directory is not an endorsement.